Interleukin-2-based therapy for metastatic renal cell cancer

The cytokine working group experience, 1989-1997

Janice P. Dutcher, Michael Atkins, Richard Fisher, Geoffrey Weiss, Kim Margolin, Fred Aronson, Jeffrey Sosman, Michael Lotze, Michael Gordon, Theodore Logan, James Mier

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

PURPOSE: This article reviews long-term follow-up data from three phase II studies conducted by the Cytokine Working Group from 1989 to 1995 that evaluated various recombinant interleukin-2 (rIL-2) -based regimens in patients with metastatic renal cell cancer. Response rates, long-term response duration, and toxicity are compared. PATIENTS AND METHODS: The Cytokine Working Group studies reviewed here investigated the safety and efficacy of two high-dose intravenous rIL-2-based regimens and two moderate- dose outpatient subcutaneous rIL-2-based regimens in patients with progressive metastatic renal cell cancer. A randomized phase II study, initiated in 1989, investigated the safety and efficacy of high-dose intravenous rIL-2 alone and high-dose intravenous rIL-2 plus recombinant interferon-α (rIFN-α). A second phase II study, initiated in 1992, tested the safety and efficacy of moderate-dose subcutaneous rIL-2 plus subcutaneous rIFN-α in the outpatient setting. The third trial, initiated in 1995, investigated a regimen consisting of the previous subcutaneous rIL-2 plus rIFN-α regimen alternating with intravenous bolus 5-fluorouracil (5-FU) plus subcutaneous rIFN-α. Median follow-up for these studies is 72 months, 48 months, and 24 months, respectively. RESULTS: The overall response rates observed with each of these regimens were similar (17% with high-dose rIL-2 alone, 11% with high-dose rIL-2/rIFN-α, 17% with outpatient subcutaneous rIL-2/rIFN-α, and 16% with outpatient rIL-2/rIFN-α, plus 5-FU/rIFN-α). However, the high-dose rIL-2 regimen produced a 7% complete response rate, compared with 0%, 4%, and 4%, respectively, with each of the other regimens. Median response duration was also much longer with high-dose intravenous rIL- 2 alone (53 months), compared with 7 months, 12 months, and 9 mouths, respectively, with each of the other regimens. CONCLUSION: Complete response rate and response duration appear to favor the high-dose intravenous rIL-2 regimen. This will require verification in a randomized study comparing the best high-dose arm (rIL-2 alone) with the best outpatient regimen (rIL- 2/IFN-α). The Cytokine Working Group is currently conducting such a study.

Original languageEnglish (US)
JournalCancer Journal from Scientific American
Volume3
Issue numberSUPPL. 1
StatePublished - 1997
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Interleukin-2
Cytokines
Interferons
Outpatients
Therapeutics
Safety
Fluorouracil
Mouth
Arm

Keywords

  • Interferon
  • Interleukin-2
  • Renal cell cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dutcher, J. P., Atkins, M., Fisher, R., Weiss, G., Margolin, K., Aronson, F., ... Mier, J. (1997). Interleukin-2-based therapy for metastatic renal cell cancer: The cytokine working group experience, 1989-1997. Cancer Journal from Scientific American, 3(SUPPL. 1).

Interleukin-2-based therapy for metastatic renal cell cancer : The cytokine working group experience, 1989-1997. / Dutcher, Janice P.; Atkins, Michael; Fisher, Richard; Weiss, Geoffrey; Margolin, Kim; Aronson, Fred; Sosman, Jeffrey; Lotze, Michael; Gordon, Michael; Logan, Theodore; Mier, James.

In: Cancer Journal from Scientific American, Vol. 3, No. SUPPL. 1, 1997.

Research output: Contribution to journalArticle

Dutcher, JP, Atkins, M, Fisher, R, Weiss, G, Margolin, K, Aronson, F, Sosman, J, Lotze, M, Gordon, M, Logan, T & Mier, J 1997, 'Interleukin-2-based therapy for metastatic renal cell cancer: The cytokine working group experience, 1989-1997', Cancer Journal from Scientific American, vol. 3, no. SUPPL. 1.
Dutcher, Janice P. ; Atkins, Michael ; Fisher, Richard ; Weiss, Geoffrey ; Margolin, Kim ; Aronson, Fred ; Sosman, Jeffrey ; Lotze, Michael ; Gordon, Michael ; Logan, Theodore ; Mier, James. / Interleukin-2-based therapy for metastatic renal cell cancer : The cytokine working group experience, 1989-1997. In: Cancer Journal from Scientific American. 1997 ; Vol. 3, No. SUPPL. 1.
@article{43da3682bb8f48c1a8adbb2d690e6a94,
title = "Interleukin-2-based therapy for metastatic renal cell cancer: The cytokine working group experience, 1989-1997",
abstract = "PURPOSE: This article reviews long-term follow-up data from three phase II studies conducted by the Cytokine Working Group from 1989 to 1995 that evaluated various recombinant interleukin-2 (rIL-2) -based regimens in patients with metastatic renal cell cancer. Response rates, long-term response duration, and toxicity are compared. PATIENTS AND METHODS: The Cytokine Working Group studies reviewed here investigated the safety and efficacy of two high-dose intravenous rIL-2-based regimens and two moderate- dose outpatient subcutaneous rIL-2-based regimens in patients with progressive metastatic renal cell cancer. A randomized phase II study, initiated in 1989, investigated the safety and efficacy of high-dose intravenous rIL-2 alone and high-dose intravenous rIL-2 plus recombinant interferon-α (rIFN-α). A second phase II study, initiated in 1992, tested the safety and efficacy of moderate-dose subcutaneous rIL-2 plus subcutaneous rIFN-α in the outpatient setting. The third trial, initiated in 1995, investigated a regimen consisting of the previous subcutaneous rIL-2 plus rIFN-α regimen alternating with intravenous bolus 5-fluorouracil (5-FU) plus subcutaneous rIFN-α. Median follow-up for these studies is 72 months, 48 months, and 24 months, respectively. RESULTS: The overall response rates observed with each of these regimens were similar (17{\%} with high-dose rIL-2 alone, 11{\%} with high-dose rIL-2/rIFN-α, 17{\%} with outpatient subcutaneous rIL-2/rIFN-α, and 16{\%} with outpatient rIL-2/rIFN-α, plus 5-FU/rIFN-α). However, the high-dose rIL-2 regimen produced a 7{\%} complete response rate, compared with 0{\%}, 4{\%}, and 4{\%}, respectively, with each of the other regimens. Median response duration was also much longer with high-dose intravenous rIL- 2 alone (53 months), compared with 7 months, 12 months, and 9 mouths, respectively, with each of the other regimens. CONCLUSION: Complete response rate and response duration appear to favor the high-dose intravenous rIL-2 regimen. This will require verification in a randomized study comparing the best high-dose arm (rIL-2 alone) with the best outpatient regimen (rIL- 2/IFN-α). The Cytokine Working Group is currently conducting such a study.",
keywords = "Interferon, Interleukin-2, Renal cell cancer",
author = "Dutcher, {Janice P.} and Michael Atkins and Richard Fisher and Geoffrey Weiss and Kim Margolin and Fred Aronson and Jeffrey Sosman and Michael Lotze and Michael Gordon and Theodore Logan and James Mier",
year = "1997",
language = "English (US)",
volume = "3",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Interleukin-2-based therapy for metastatic renal cell cancer

T2 - The cytokine working group experience, 1989-1997

AU - Dutcher, Janice P.

AU - Atkins, Michael

AU - Fisher, Richard

AU - Weiss, Geoffrey

AU - Margolin, Kim

AU - Aronson, Fred

AU - Sosman, Jeffrey

AU - Lotze, Michael

AU - Gordon, Michael

AU - Logan, Theodore

AU - Mier, James

PY - 1997

Y1 - 1997

N2 - PURPOSE: This article reviews long-term follow-up data from three phase II studies conducted by the Cytokine Working Group from 1989 to 1995 that evaluated various recombinant interleukin-2 (rIL-2) -based regimens in patients with metastatic renal cell cancer. Response rates, long-term response duration, and toxicity are compared. PATIENTS AND METHODS: The Cytokine Working Group studies reviewed here investigated the safety and efficacy of two high-dose intravenous rIL-2-based regimens and two moderate- dose outpatient subcutaneous rIL-2-based regimens in patients with progressive metastatic renal cell cancer. A randomized phase II study, initiated in 1989, investigated the safety and efficacy of high-dose intravenous rIL-2 alone and high-dose intravenous rIL-2 plus recombinant interferon-α (rIFN-α). A second phase II study, initiated in 1992, tested the safety and efficacy of moderate-dose subcutaneous rIL-2 plus subcutaneous rIFN-α in the outpatient setting. The third trial, initiated in 1995, investigated a regimen consisting of the previous subcutaneous rIL-2 plus rIFN-α regimen alternating with intravenous bolus 5-fluorouracil (5-FU) plus subcutaneous rIFN-α. Median follow-up for these studies is 72 months, 48 months, and 24 months, respectively. RESULTS: The overall response rates observed with each of these regimens were similar (17% with high-dose rIL-2 alone, 11% with high-dose rIL-2/rIFN-α, 17% with outpatient subcutaneous rIL-2/rIFN-α, and 16% with outpatient rIL-2/rIFN-α, plus 5-FU/rIFN-α). However, the high-dose rIL-2 regimen produced a 7% complete response rate, compared with 0%, 4%, and 4%, respectively, with each of the other regimens. Median response duration was also much longer with high-dose intravenous rIL- 2 alone (53 months), compared with 7 months, 12 months, and 9 mouths, respectively, with each of the other regimens. CONCLUSION: Complete response rate and response duration appear to favor the high-dose intravenous rIL-2 regimen. This will require verification in a randomized study comparing the best high-dose arm (rIL-2 alone) with the best outpatient regimen (rIL- 2/IFN-α). The Cytokine Working Group is currently conducting such a study.

AB - PURPOSE: This article reviews long-term follow-up data from three phase II studies conducted by the Cytokine Working Group from 1989 to 1995 that evaluated various recombinant interleukin-2 (rIL-2) -based regimens in patients with metastatic renal cell cancer. Response rates, long-term response duration, and toxicity are compared. PATIENTS AND METHODS: The Cytokine Working Group studies reviewed here investigated the safety and efficacy of two high-dose intravenous rIL-2-based regimens and two moderate- dose outpatient subcutaneous rIL-2-based regimens in patients with progressive metastatic renal cell cancer. A randomized phase II study, initiated in 1989, investigated the safety and efficacy of high-dose intravenous rIL-2 alone and high-dose intravenous rIL-2 plus recombinant interferon-α (rIFN-α). A second phase II study, initiated in 1992, tested the safety and efficacy of moderate-dose subcutaneous rIL-2 plus subcutaneous rIFN-α in the outpatient setting. The third trial, initiated in 1995, investigated a regimen consisting of the previous subcutaneous rIL-2 plus rIFN-α regimen alternating with intravenous bolus 5-fluorouracil (5-FU) plus subcutaneous rIFN-α. Median follow-up for these studies is 72 months, 48 months, and 24 months, respectively. RESULTS: The overall response rates observed with each of these regimens were similar (17% with high-dose rIL-2 alone, 11% with high-dose rIL-2/rIFN-α, 17% with outpatient subcutaneous rIL-2/rIFN-α, and 16% with outpatient rIL-2/rIFN-α, plus 5-FU/rIFN-α). However, the high-dose rIL-2 regimen produced a 7% complete response rate, compared with 0%, 4%, and 4%, respectively, with each of the other regimens. Median response duration was also much longer with high-dose intravenous rIL- 2 alone (53 months), compared with 7 months, 12 months, and 9 mouths, respectively, with each of the other regimens. CONCLUSION: Complete response rate and response duration appear to favor the high-dose intravenous rIL-2 regimen. This will require verification in a randomized study comparing the best high-dose arm (rIL-2 alone) with the best outpatient regimen (rIL- 2/IFN-α). The Cytokine Working Group is currently conducting such a study.

KW - Interferon

KW - Interleukin-2

KW - Renal cell cancer

UR - http://www.scopus.com/inward/record.url?scp=0031424976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031424976&partnerID=8YFLogxK

M3 - Article

VL - 3

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - SUPPL. 1

ER -